Cannabidiol Eases Heart Failure Damage by Rejuvenating Aging Cells and Restoring Organelle Communication

Heart failure with preserved ejection fraction, known as HFpEF, is one of the most frustrating puzzles in modern cardiology. Patients arrive with the classic symptoms of heart failure—breathlessness, fatigue, fluid retention—yet when clinicians measure the ejection fraction, the heart appears to be pumping normally. The problem lies deeper, in the heart’s inability to relax and fill properly between beats. Despite decades of research, HFpEF remains stubbornly resistant to the therapies that have transformed other forms of heart failure, and its prevalence continues to climb as populations age and obesity rates rise. Now, a team of researchers in Mexico has reported that cannabidiol, the non-psychoactive compound derived from cannabis, may offer a way forward, and their work points to an unexpected trio of biological culprits: prematurely aged cells, runaway inflammation, and damaged communication lines between two of the cell’s most important organelles.

The study, published in the Journal of Molecular Medicine, was led by Alejandro Silva-Palacios, Alejandra María Zúñiga-Muñoz, and Cecilia Zazueta of the National Institute of Cardiology Ignacio Chávez in Mexico City, together with collaborators at the National Autonomous University of Mexico and Tecnológico de Monterrey. The researchers set out to test whether cannabidiol, commonly abbreviated as CBD, could protect the heart in an animal model that closely mimics the human condition. They induced HFpEF in mice by combining a high-fat diet with L-NAME, a compound that inhibits nitric oxide synthesis and drives the nitrosative stress considered central to the disease. Over eight weeks, the animals developed the hallmark features of HFpEF: cardiac fibrosis, diastolic dysfunction, and systemic metabolic and inflammatory disturbances. CBD was then administered subcutaneously every three days, a dosing interval chosen to maintain sustained exposure to the compound.

The results were nuanced but striking. CBD did not shrink the enlarged, hypertrophied hearts of the diseased animals; cardiac hypertrophy persisted despite treatment. However, the compound produced meaningful improvements where they mattered most for HFpEF patients. Treated animals showed reduced cardiac fibrosis, the stiffening scar tissue that prevents the heart muscle from relaxing, and their diastolic function improved measurably. The researchers assessed hemodynamic performance using invasive pressure-volume loop analysis, the gold standard for evaluating how the ventricle fills and ejects blood, and complemented these measurements with histological examination and markers of oxidative stress. The improvement in filling dynamics, rather than pumping strength, is precisely the kind of benefit that HFpEF patients need, since their hearts fail not because they pump too weakly but because they cannot relax enough to refill.

To understand how CBD achieved these effects, the team turned their attention to cellular senescence, the state in which cells stop dividing but refuse to die, instead lingering in tissues and secreting a toxic cocktail of inflammatory molecules. This senescence-associated secretory phenotype, or SASP, has emerged as a key driver of age-related diseases, and growing evidence links it to heart failure. In the HFpEF mice, senescent cells had accumulated in the heart, and circulating cytokine levels were elevated, consistent with a body-wide SASP-driven inflammatory state. CBD treatment markedly reduced the accumulation of these senescent cells and lowered systemic cytokine levels. The finding suggests that CBD may act as a partial senotherapeutic, clearing or calming the aged cells that fuel chronic inflammation in the failing heart.

The second major target was the NLRP3 inflammasome, a molecular machine inside immune and cardiac cells that, when activated, triggers caspase-1 and the release of potent proinflammatory cytokines such as interleukin-1 beta. NLRP3 activation has been implicated in cardiac remodeling, pulmonary artery changes, and general inflammation in HFpEF, and pharmacological inhibitors of this inflammasome have already shown benefit in mouse models of the disease. In the current study, CBD suppressed the NLRP3-mediated proinflammatory state, adding to a growing body of evidence that the compound can dampen inflammasome signaling. Previous work had shown that CBD inhibits NLRP3 activation in human monocytes through modulation of the P2X7 receptor, and that cannabinoids can attenuate cytokine storms driven by inflammasome pathways. The new findings extend this anti-inflammatory repertoire into the HFpEF setting.

Perhaps the most novel contribution of the study lies in its third focus: the mitochondria-endoplasmic reticulum contact sites, abbreviated MERCSs. These are microscopic junctions where the membranes of mitochondria, the cell’s power plants, and the endoplasmic reticulum, its protein-folding and calcium-storage factory, come into close apposition. At these contact points, the two organelles exchange calcium, lipids, and stress signals, coordinating everything from energy metabolism to cell death decisions. When MERCSs become excessive or disorganized, calcium overload and mitochondrial destabilization can activate the NLRP3 inflammasome, linking organelle architecture directly to inflammation. Using transmission electron microscopy, immunofluorescence, and RT-qPCR, the researchers found that in HFpEF the integrity of these contact sites was compromised, and that CBD treatment preserved inter-organelle distance and MERCSs structure.

This is the first demonstration, according to the authors, that CBD modulates MERCSs communication to regulate senescence and inflammation in HFpEF. The finding ties together threads that had previously run in parallel. Earlier work from the same group had shown that senotherapy in obese rats could act through a MERCSs/Nrf2 interaction, and other studies had established that disrupted sarcoplasmic reticulum-mitochondrial contacts underlie contractile dysfunction in atrial fibrillation, while enhanced tethering can trigger adaptive cardiac remodeling. In diabetes, hyperglycemia-driven promotion of mitochondria-associated endoplasmic reticulum membranes contributes to cardiomyopathy, and in aged hearts, defective calcium exchange between these organelles impairs function. By preserving the geometry of these junctions, CBD appears to prevent the calcium mishandling and mitochondrial stress that ignite inflammasome activation, thereby interrupting a vicious cycle in which organelle damage feeds inflammation, which in turn accelerates cellular aging.

The implications extend beyond the laboratory. HFpEF accounts for roughly half of all heart failure cases, and its burden is growing with the obesity and diabetes epidemics. Current treatment options remain limited, with recent trials of sodium-glucose cotransporter-2 inhibitors offering only partial benefit, and one such agent, empagliflozin, has been shown to protect against HFpEF partly by inhibiting a senescence-associated signaling axis. Pharmacological clearance of senescent cells has independently been shown to reduce inflammation, endothelial damage, and cardiac fibrosis in HFpEF models. The convergence of these findings suggests that targeting the biology of aging itself—senescent cells, their secretory products, and the organelle networks that control cellular stress—may be a viable therapeutic strategy for a disease that has defied conventional approaches.

CBD brings its own compelling profile to this strategy. Unlike tetrahydrocannabinol, it does not produce intoxication, and it has already been approved for certain forms of epilepsy, giving clinicians experience with its safety profile. Prior animal studies have shown that CBD attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory signaling in diabetic cardiomyopathy, prevents heart failure dysfunction through preservation of mitochondrial function and calcium handling, and promotes cardiomyocyte proliferation after myocardial infarction. A clinical trial, the ARCHER study, is currently evaluating CBD’s impact on myocardial recovery in patients with acute myocarditis. The new HFpEF findings add another potential indication to this expanding list, though the authors caution that the signaling pathways connecting MERCSs preservation to reduced senescence and inflammation still need to be fully characterized.

Important questions remain before CBD can be considered a treatment for HFpEF. The study was conducted in mice, and the dose, route, and timing of administration would need careful translation to humans. The failure to reduce hypertrophy suggests that CBD addresses some but not all of the disease’s pathological drivers, and it is unclear whether starting treatment earlier or later would change the outcome. Nevertheless, by identifying premature senescence, NLRP3-mediated inflammation, and MERCSs integrity as linked, druggable targets in HFpEF, the Mexican team has offered both a mechanistic explanation for CBD’s cardioprotective effects and a roadmap for the next generation of experiments. For a disease that affects millions and has resisted nearly every therapeutic attempt, the idea that a well-tolerated plant-derived compound might restore youthful communication between a cell’s organelles and quiet the inflammatory noise of aging tissue is a prospect worth watching closely.

Subject of Research: The cardioprotective effects of cannabidiol in heart failure with preserved ejection fraction through modulation of cellular senescence, NLRP3 inflammation, and mitochondria-endoplasmic reticulum contact sites.

Article Title: Prospective associations of premature senescence, inflammation, and MERCSs in the cardioprotective effect of CBD in HFpEF

Article References: Silva-Palacios, A., Zúñiga-Muñoz, A. M., Soria-Castro, E., Álvarez-León, E., García-Niño, W. R., Navarrete-Anastasio, G., Raza, D., Aparicio-Trejo, O. E., Ramírez-Carreto, R. J., Salas-Venegas, V., Chavarría, A., Maldonado-Ruíz, R. A., Alves-Figueiredo, H., García-Rivas, G., & Zazueta, C. (2026). Prospective associations of premature senescence, inflammation, and MERCSs in the cardioprotective effect of CBD in HFpEF. Journal of Molecular Medicine, 104(1), Article 109. https://doi.org/10.1007/s00109-026-02715-4

Image Credits: AI Generated

DOI: 10.1007/s00109-026-02715-4

Keywords: heart failure, HFpEF, cannabidiol, cellular senescence, SASP, NLRP3 inflammasome, MERCSs, mitochondria, endoplasmic reticulum, cardiac fibrosis, diastolic dysfunction, inflammation